Risk of Fingolimod Rebound After Switching to Cladribine or Rituximab in MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Sclerosis and Related Disorders
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
Mult Scler Relat Disord 2022 Apr 17;62(2022)103812, GO Nygaard, H Torgauten, L Skattebøl, EA Høgestøl, P Sowa, KM Myhr, Ø Torkildsen, EG CeliusFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.